Natixis Advisors, L.P. Exelixis, Inc. Transaction History
Natixis Advisors, L.P.
- $51.3 Billion
- Q3 2024
A detailed history of Natixis Advisors, L.P. transactions in Exelixis, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 29,113 shares of EXEL stock, worth $1.01 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,113
Previous 23,062
26.24%
Holding current value
$1.01 Million
Previous $518,000
45.75%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding EXEL
# of Institutions
501Shares Held
244MCall Options Held
2.54MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.17 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$1.02 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$885 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$535 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$399 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.2B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...